Antimalarial drug quality in Africa

Journal of Clinical Pharmacy and Therapeutics

Volumn 32, Issue 5, 2007, Pages 429-440

  Amin, A A ^a,c   Kokwaro, G O ^a,b  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

Africa; Antimalarial drugs; Bioavailability; Content; Dissolution; Impurity; Quality

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMISININ; CHLOROQUINE; DIHYDROARTEMISININ; FALCIDIN; FANSIDAR; MEFLOQUINE; PROGUANIL; QUININE; UNCLASSIFIED DRUG;

AFRICA; AREA UNDER THE CURVE; DRUG BIOAVAILABILITY; DRUG COATING; DRUG CONTAMINATION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG IMPURITY; DRUG LABELING; DRUG MARKETING; DRUG QUALITY; DRUG SOLUBILITY; DRUG STABILITY; DRUG SURVEILLANCE PROGRAM; HUMAN; MALARIA FALCIPARUM; MEDICAL LITERATURE; MEDLINE; PEER REVIEW ORGANIZATION; PLASMODIUM FALCIPARUM; PLASMODIUM MALARIAE; PUBLICATION; REVIEW; SHELF LIFE; WORLD HEALTH ORGANIZATION;

AFRICA; ANTIMALARIALS; ARTEMISININS; BIOLOGICAL AVAILABILITY; DOSAGE FORMS; DRUG COMBINATIONS; DRUG STABILITY; DRUG STORAGE; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; PYRIMETHAMINE; QUALITY CONTROL; SESQUITERPENES; SULFADOXINE;

EID: 34548616586     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2007.00847.x     Document Type: Review

References (69)

1. WHO (1999) Effective drug regulation: what can countries do? Geneva: WHO, 1 53.
2. MCA (1997) Towards safe medicines. A guide to the control of safety, quality and efficacy of human medicines in the United Kingdom. Revised edition 1997. London: Medicines Control Agency (MCA), 1 93.
3. Penn RG (1979) The state control of medicines: the first 3000 years. British Journal of Clinical Pharmacology, 8, 293 305.
4. Shah RR (2001) Thalidomide, drug safety and early drug regulation in the UK. Adverse Drug Reaction and Toxicology Review, 20, 199 255.
5. Murray CJL, Lopez AD (1997) Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet, 349, 1269 1276.
6. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI (2005) The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature, 434, 214 217.
7. McCombie SC (1996) Treatment seeking for malaria: a review of recent research. Social Science and Medicine, 43, 933 945.
8. Spencer H, Kaseje D, Roberts J, Huong A (1987) Consumption of chloroquine phosphate provided for treatment of malaria by volunteer village health worker in Saradidi, Kenya. Annals of Tropical Medicine and International Health, 81, 116 123.
9. Winstanley PA, Ward SA, Snow RW, Breckenridge AM (2004) Therapy of falciparum malaria in sub-Saharan Africa: from molecule to policy. Clinical Microbiology Reviews, 17, 612 637.
10. Shretta R, Omumbo J, Rapuoda BA, Snow RW (2000) Using evidence to change antimalarial drug policy in Kenya. Tropical Medicine and International Health, 5, 755 764.
11. MoH (2004) National symposium on next anti-malaria treatment policy in Kenya. 5th-6th April 2004. Naivasha: Ministry of Health, Republic of Kenya, 1 29.
12. IOM (2004) Saving lives, buying time: economics of malaria drugs in an age of resistance. Washington: The National Academies Press.
13. Cockburn P, Newton PN, Agyarko EK, Akunyili D, White NJ (2005) The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Medicine, 2, e100.
14. Gibson L (2004) Counterfeits of impotence drug appear in the United Kingdom. British Medical Journal, 329, 532.
15. Dong BJ, Hauck WW, Gambertoglio JG, Gee L, White JR, Bubp JL, Greenspan FS (1997) Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. Journal of American Medical Association, 277, 1205 1213.
16. Shakoor O, Taylor RB, Behrens RH (1997) Assessment of the incidence of substandard drugs in developing countries. Tropical Medicine and International Health, 2, 839 845.
17. WHO (1999) Counterfeit drugs: guidelines for the development of measures to combat counterfeit drugs. Geneva: WHO, 1 60.
18. Greenwood BM, Bradley AK, Greenwood AM et al. (1987) Mortality and morbidity from malaria among children in a rural area of The Gambia, West Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene, 81, 478 486.
19. Newton PN, McGready R, Fernandez F et al. (2006) Manslaughter by fake artesunate in Asia-will Africa be next? PLoS Medicine, 3, e197.
20. Aldhous P (2005) Murder by medicine. Nature, 434, 132 136.
21. Aulton ME (ed 2001) Pharmaceutics. Churchill Livingstone: The Science of Dosage Form Design.
22. USP (2000) United States Pharmacopoeia, USP 24 NF 19 edn. Rockville: Pharmacopoeial Convention INC.
23. BP (2000) British Pharmacopoeia, Vol. II. London: The Stationery Office.
24. Amin AA, Snow RW, Kokwaro GO (2005) The quality of sulfadoxine- pyrimethamine and amodiaquine in the Kenyan retail sector. Journal of Clinical Pharmacy and Therapeutics, 30, 559 565.
25. Lucas TI, Bishara RH, Seevers RH (2004) A stability program for the distribution of drug products. Pharmaceutical Technology, July 2, 68 73.
26. U.S. Department of Health and Human Services (2003) Guidance for industry Q1A(R2) stability testing of new drug substances and products. November 2003, ICH Revision 2. U.S. Department of Health and Human Services, Rockville.
27. Vadas EB (1990) Stability of pharmaceutical products. In: Gennaro AR, ed. Remminton's pharmaceutical sciences, 18th edn. Pennsylvania: Mack Publishing Company, 1503 1512.
28. Wagner JG (1993) Bioavailability. Pharmacokinetics for the pharmaceutical scientist. Lancaster: Technomic Publishing Company, 187 197.
29. Hebron Y, Tettey JNA, Pournamdari M, Watson DG (2005) The chemical and pharmaceutical equivalence of sulfadoxine/pyrimethamine tablets sold on the Tanzanian market. Journal of Clinical Pharmacy and Therapeutics, 30, 575 581.
30. Kayumba PC, Risha PG, Shewiyo D et al. (2004) The quality of essential antimicrobial and antimalarial drugs marketed in Rwanda and Tanzania: influence of tropical storage conditions on in vitro dissolution. Journal of Clinical Pharmacy and Therapeutics, 29, 331 338.
31. Ogwal-Okeng JW, Okello DO, Odyek O (1998) Quality of oral and parenteral chloroquine in Kampala. East African Medical Journal, 75, 692 694.
32. Ogwal-Okeng JW, Owino E, Obua C (2003) Chloroquine in the Ugandan market fails quality test: a pharmacovigilance study. African Health Sciences, 3, 2 6.
33. Minzi OM, Moshi MJ, Hipolite D, Massele AY, Tomson G, Ericsson O, Gustafsson LL (2003) Evaluation of the quality of amodiaquine and sulphadoxine/ pyrimethamine tablets sold by private wholesale pharmacies in Dar Es Salaam Tanzania. Journal of Clinical Pharmacology and Therapeutics, 28, 117 122.
34. Rimoy GH, Moshi MJ, Massele AY (2002) Comparative bioavailability of oral sugar-coated and plain formulation of choloroquine phosphate marketed in Tanzania. Tropical Doctor, 32, 15 17.
35. Nsimba SED, Aden-Abdi Y, Rimoy G, Massele AY, Alm C, Ericsson O, Gustafsson L (2001) Comparative in vitro and in vivo study of a sugar-coated chloroquine preparation marketed in Tanzania versus an ordinary brand. Journal of Clinical Pharmacy and Therapeutics, 26, 43 48.
36. Idowu OA, Alapara SB, Lasisi AA (2006) Assessment of quality of chloroquine tablets sold by drug vendors in Abeokuta, Nigeria. Tanzania Health Research Bulletin, 8, 45 46.
37. Gaudiano MC, Di Maggio A, Cocchieri E, Antoniella E, Bertocchi P, Alimonti S, Valvo L (2007) Medicines informal market in Congo, Burundi and Angola: counterfeit and sub-standard antimalarials. Malaria Journal, 6, 22.
38. Risha PG, Shewiyo D, Msami A, Masuki G, Vergote G, Vervaet C (2002) In vitro evaluation of the quality of essential drugs on the Tanzanian market. Tropical Medicine and International Health, 7, 701 707.
39. Ballereau F, Prazuck T, Schrive I, Lafleuriel MT, Rozec D, Fisch A, Lafaix C (1997) Stability of essential drugs in the field: results of a study conducted over a two-year period in Burkina Faso. American Journal of Tropical Medicine and Hygiene, 57, 31 36.
40. Taylor RB, Shakoor O, Behrens RH et al. (2001) Pharmacopoeial quality of drugs supplied by Nigerian pharmacies. Lancet, 357, 1933 1936.
41. Odeniyi MA, Adegoke OA, Adereti RB, Odeku OA, Itiola OA (2003) Comparative analysis of eight brands of sulfadoxine-pyrimethamine tablets. Tropical Journal of Pharmaceutical Research, 2, 161 167.
42. Abdi YA, Rimoy G, Ericsson O, Alm C, Massele AY (1995) Quality of chloroquine preparations marketed in Dar es Salaam, Tanzania. Lancet, 346, 1161.
43. Sesay MM (1994) Expiry dates on pharmaceuticals-some worrying realities in Sierra Leone. International Pharmacy Journal, 8, 202 206.
44. Mahmoud BM, Ali HM, Homeida MMA, Bennett JL (1994) Bioequivalence of five chloroquine brands marketed in Sudan. International Pharmacy Journal, 8, 164 167.
45. Sowunmi A, Salako LA, Ogunbona FA (1994) Bioavailability of sulphate and dihydrochloride salts of quinine. African Journal of Medicine and Medical Sciences, 23, 275 278.
46. Kibwage IO, Ngugi JK (2000) Sulphadoxine/ pyrimethamine tablet products on the Kenyan market: quality concerns. East and Central African Journal of Pharmaceutical Sciences, 3, 14 19.
47. Murphy SA, Mberu EK (1994) A study of the comparative bioavailability of pyrimethamine- sulfadoxine obtained from two oral preparations. East African Medical Journal, 71, 328 329.
48. Atemnkeng MA, De Cock K, Plaizier-Vercammen J (2007) Quality control of active ingredients in artemisinin-derivative antimalarials within Kenya and DR Congo. Tropical Medicine and International Health, 12, 68 74.
49. WHO (2003) The quality of antimalarials. A study in selected African countries. Geneva: World Health Organization, 1 67.
50. WHO (1995) La qualite des medicaments sur le marche pharmaceutique africain. Etude analytique dans trois pays: Cameroun, Madagascar, Tchad. WHO/ DAP/95.3. Geneva: World Health Organization.
51. Maitai CK, Kofi Tsekpo WM, Wakori E, Wangia C, Mkoji L, Githiga IM (1982) Drug quality control in Kenya - preliminary observations. East African Medical Journal, 59, 399 403.
52. Ogeto JO, Maitai CK, Wangia C et al. (1983) Practical therapeutical drug quality control in Kenya - further observations. East African Medical Journal, 60, 439 443.
53. Mang'era KO, Rutere GK, Thuranira JK et al. (1992) Drug quality control work at Drug Analysis Research Unit: observations during 1987-1990. Pharmaceutical Journal of Kenya, 4, 66 69.
54. Thoithi GN, Abuga KO, Nguyo JM, Mukindia G, Kin'gondu O, Ngugi JK, Kibwage IO (2002) Drug quality control in Kenya: observations in Drug Analysis and Research Unit during the period 1996-2000. East and Central African Journal of Pharmaceutical Sciences, 5, 28 32.
55. Kibwage IO, Ogeto JO, Maitai CK, Rutere G, Thuranira J, Ochieng' A (1992) Drug quality control work in DARU: observations during 1983-1986. East African Medical Journal, 69, 577 580.
56. Kibwage IO, Thuranira JK, Gathu L, Githiga IM, Nguyo JM, Ngugi JK, King'ondu O (1999) Drug quality control work in Drug Analysis and Research Unit: observations during 1991-1995. East and Central African Journal of Pharmaceutical Sciences, 2, 32 36.
57. Basco LK. (2004) Molecular epidemiology of malaria in Cameroon. XIX. Quality of antimalarial drugs used for self-medication. American Journal of Tropical Medicine and Hygiene, 70, 245 250.
58. Erhun WO, Babalola OO, Erhun MO (2001) Drug regulation and control in Nigeria: the challenge of counterfeit drugs. Journal of Health and Population in Developing Countries, 4, 23 34.
59. Kron MA (1996) Substandard primaquine phosphate for US Peace Corps personnel. Lancet, 348, 1453 1454.
60. Basco LK, Ringwald P, Manene AB, Chandenier J (1997) False chloroquine resistance in Africa. Lancet, 350, 224.
61. Reithinger R (2001) Bogus antimalarials: a forgotten tale. Trends in Parasitology, 17, 359.
62. Green MD, Mount DL, Wirtz RA (2001) Authentication of artemether, artesunate and dihydroartemisinin antimalarial tablets using simple colorimetric method. Tropical Medicine and International Health, 6, 980 982.
63. Green MD, Mount DL, Wirtz RA, White NJ (2000) A colorimetric field method to assess the authenticity of drugs sold as the antimalarial artesunate. Journal of Pharmaceutical and Biomedical Analysis, 24, 65 70.
64. Jahnke RWO, Kusters G (2001) Low-cost quality assurance of medicines using the GPHF-Minilab. Drug Information Journal, 35, 941 945.
65. TM drug product using accurate mass electrospray ionisation mass spectrometry, accurate mass tandem mass spectrometry and liquid chromatography/mass spectrometry. Rapid Communications in Mass Spectrometry, 17, 215 221.
66. Amin AA (2005) Range, quality and costs of antimalarial drugs available in the retail sector in Kenya. Milton Keynes: Open University.
67. Snow RW, Eckert E, Teklehaimanot A (2003) Estimating the needs for artesunate-based combination therapy for malaria case-management in Africa. Trends in Parasitology, 19, 363 369.
68. Nzila AM, Nduati E, Mberu EK, Sibley CH, Monks SA, Winstanley PA, Watkins WM (2000) Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethamine/sulfadoxine compared with the short-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. Journal of Infectious Diseases, 181, 2023 2028.
69. Watkins WM, Mosobo M (1993) Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Transactions of the Royal Society of Tropical Medicine and Hygiene, 87, 75 78.